<DOC>
	<DOCNO>NCT01317667</DOCNO>
	<brief_summary>This study Phase 1 , escalate , multiple-dose , single-center study evaluate safety immunogenicity RVEc vaccine . The two principal hypothesis test : RVEc vaccine display acceptable safety profile determine adverse event data RVEc vaccine elicit ELISA immunoglobulin G ( IgG ) titer great equal 1:500 toxin-neutralizing antibody ( TNA ) anti-ricin toxin-neutralizing antibody titer great equal 1:50 vaccine recipient .</brief_summary>
	<brief_title>Safety Immunogenicity Study Recombinant Ricin Toxin A-Chain Vaccine ( RVEcâ„¢ )</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>Study subject must 1850 year old . Subjects must weigh least 110 pound . Subjects must good health judge medical history , physical examination , EKG chest xray , complete blood count ( CBC ) differential , clinical chemistry , urinalysis , hepatitis serology , HIV antibody test , medically clear participation investigator . If HIV hepatitis test positive , individual provide counsel referral health care . Females childbearing potential must negative pregnancy test vaccination day dose agree become pregnant breastfeed 3 month last dose vaccine willing use reliable form contraception study . Study subject must read sign approve informed consent . Study subject must willing complete subject diary card vaccination . Study subject must willing return followup visit . Study subject must agree report adverse event ( AE ) may may associate administration investigational product 9month followup visit . Study subject report serious adverse event duration study . Body weight less 110 pound . Acute chronic medical condition immunodeficiency medical condition medical treatment , medication , dietary supplement , investigator 's opinion , would impair subject 's ability respond vaccination . Severe hypersensitivity vaccine ( anaphylaxis , angioedema , bronchospasm , laryngospasm ) . History asthma , chronic obstructive pulmonary disease , current/residual disease lung . Clinically significant abnormal laboratory test . Current smoker . Any known allergy sodium succinate , Tween20 ( detergent ) , aluminum hydroxide , kanamycin . Previously receive ricin toxin vaccine antibody ricin toxin protein . Receipt license vaccine within 30 day prior start study plan receive vaccine initial 9 month study ( exception inactivate influenza vaccine receive least 30 day RVEc Dose 3 ) . Receipt investigational drug/test product within 30 day prior entry within initial 9 month study . Females : Pregnant breastfeeding . Enrolled another great minimal risk study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Ricin</keyword>
	<keyword>RVEc</keyword>
</DOC>